MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

This study is testing an innovative approach for recurrent brain cancer (glioblastoma or high-grade glioma): using specially engineered stem cells loaded with a cancer-killing virus (DNX-2401) to directly target tumors that have returned after initial treatment. The stem cells act as delivery vehicles, traveling through the brain to find and deliver the virus to tumor cells. **You may be eligible if...** - You have a confirmed diagnosis of recurrent glioblastoma, gliosarcoma, anaplastic astrocytoma (IDH wild-type), or IDH-mutant grade 4 astrocytoma - Your tumor has come back after initial treatment - Your tumor is at least 1 cm and no more than 5 cm in diameter - You are in good general health and able to give informed consent **You may NOT be eligible if...** - Your tumor has spread widely or is rapidly growing outside the main mass - You require immune-suppressing doses of steroids - You are pregnant or breastfeeding - You have active infections or serious other medical conditions Talk to your doctor to see if this trial is right for you.